AngioDynamics (Nasdaq:ANGO) announced today that it received CE mark approval for its Auryon atherectomy system. Latham, New York-based AngioDynamics designed Auryon for the treatment of peripheral artery disease (PAD). That includes critical limb ischemia (CLI) and in-stent restenosis (ISR). Auryon uses revolutionary solid-state laser … [Read more...] about AngioDynamics wins CE mark for atherectomy system
AngioDynamics
AngioDynamics wins CE Mark for AlphaVac F18
AngioDynamics announced this week that it received CE Mark approval for its AlphaVac F18 system, which treats pulmonary embolism and removes thrombi and emboli. AlphaVac F18 is an emergent first-line device the company designed for the non-surgical removal of thromboemboli from the pulmonary arteries and for the treatment of pulmonary … [Read more...] about AngioDynamics wins CE Mark for AlphaVac F18
FDA clears AngioDynamics’ Auryon XL catheter
AngioDynamics announced today that it received FDA 510(k) clearance for its Auryon XL catheter for use with the Auryon atherectomy system in treating peripheral arterial disease (PAD). The Auryon XP catheter is a 225 cm radial access catheter available in 0.9 mm and 1.5 mm diameters to expand treatment access points in atherectomy procedures in … [Read more...] about FDA clears AngioDynamics’ Auryon XL catheter
Merit Medical spends $132.5M on acquisitions to expand its offerings
AngioDynamics (Nasdaq:ANGO) announced that it completed the sale of its dialysis product portfolio to Merit Medical Systems. It was part of a series of product acquisitions worth $132.5 million that Merit (Nasdaq: MMSI) has announced. Latham, New York-based AngioDynamics sold its dialysis portfolio and the BioSentry product for $100 million … [Read more...] about Merit Medical spends $132.5M on acquisitions to expand its offerings
AngioDynamics rises on Street-beating Q4 revenues
AngioDynamics (NSDQ:ANGO) shares ticked up this morning on fourth-quarter results that beat the consensus revenue forecast. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$19.5 million, or -51¢ per share, on sales of $76.8 million for the three months ended May 31, 2021, for an 87.6% bottom-line gain … [Read more...] about AngioDynamics rises on Street-beating Q4 revenues
AngioDynamics mechanical thrombectomy system wins FDA clearance
AngioDynamics (NSDQ:ANGO) today said it received FDA 510(k) clearance for its AlphaVac mechanical thrombectomy system. AlphaVac is an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the non-surgical removal of thrombi or emboli from the vasculature. Latham, N.Y.-based AngioDynamics designed the system with a … [Read more...] about AngioDynamics mechanical thrombectomy system wins FDA clearance
Medline Industries buys Namic business from AngioDynamics
Medline Industries will pay $167.5 million to acquire the Namic fluid management business from AngioDynamics (NSDQ:ANGO), the companies announced today. The deal, subject to customary closing conditions, is expected to close in the summer. It will allow Medline to acquire the manifolds, contrast management systems, closed fluid systems, … [Read more...] about Medline Industries buys Namic business from AngioDynamics
